Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Colin Goding’s lab study the expression of ABCB5, with implications for drug resistance

To understand melanoma disease progression and the response to therapy, it is helpful to define markers of the different disease states. The ABCB5 transporter has been implicated in drug resistance in melanoma and has also been used as a marker of slow cycling melanoma-initiating cells, although its use for this purpose has remained controversial. In this article published in Pigment Cell and Melanoma Research, Pakavarin Louphrasitthiphol and Jagat Chauhan from Prof. Colin Goding’s lab investigate the expression of ABCB5 further. The researchers found that ABCB5 is activated by the melanoma master regulator MITF. Since MITF is itself associated with melanoma differentiation rather than melanoma-initiating cells, this result further questions the use of ABCB5 as a marker of the melanoma-initiating cell population. Additionally, the expression of ABCB5 in differentiated melanoma cells may contribute to drug resistance in this population.

Similar stories

Delving into MITF’s regulatory network in melanoma

Research from Ludwig Oxford’s Colin Goding and Department of Oncology’s Francesca Buffa uncovers new genes regulated by MITF in the context of the melanoma tumour microenvironment.

Ludwig Oxford retreat 2022 – a recap

On 13-14th June 2022, the Oxford Branch of the Ludwig Institute for Cancer Research held their annual retreat to discuss key scientific advances within the Branch and beyond.